started · updated
Egyptian Drug Authority discusses localizing pharmaceutical industries with Novartis
The Egyptian Drug Authority (EDA) is engaging in strategic discussions with Novartis to localize biopharmaceutical industries and enhance technology transfer within Egypt. During meetings between EDA Chairman Dr. Ali El-Ghamrawy and Novartis leadership, including Tracy Goodridge, the parties discussed expanding local manufacturing for export and improving the availability of innovative treatments for rare diseases.
In a related development, Novartis Egypt received EDA approval for Kisqali, a treatment for early-stage breast cancer in specific high-risk female patients.
Additionally, Dr. El-Ghamrawy participated in the opening of the 'Egy Health' conference and exhibition. The event serves as a platform for healthcare and pharmaceutical stakeholders to exchange expertise and explore new partnerships to support Egypt's goal of becoming a regional hub for pharmaceutical manufacturing and medical supplies.
Entities
Ali El-Ghamrawy · Egypt · Egyptian Drug Authority · Novartis